IMV Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMVIF research report →
Price Chart
About the company
IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers.
- CEO
- Andrew Hall
- IPO
- 2013
- Employees
- 63
- HQ
- Dartmouth, NS, CA
Get TickerSpark's AI analysis on IMVIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $117
- P/E
- -0.18
- PEG
- -0.02
- P/S
- 0.00
- P/B
- -0.99
- EV/EBITDA
- -0.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -495.17%
- ROIC
- -172.47%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-962,298-79.5%
- Op Income
- $-38,671,513
- Net Income
- $-36,485,694-0.6%
- EPS
- $-4.37+10.6%
- OCF Growth
- -1.0%
- FCF Growth
- +0.1%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.30
- RSI (14)
- 52
- Avg Volume
- 92
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IMV said its DPX-based cancer vaccine is showing early efficacy in highly refractory lymphoma and other cancers, while it is also exploring strategic options amid difficult small-cap biotech markets.· March 16, 2023
- VITALIZE is nearing full Stage 1 enrollment, with management saying it should complete in the next month and reach 30-plus patients across two arms.
- Management said the early VITALIZE data showed confirmed complete responses in patients with heavily pretreated DLBCL, with no systemic toxicity observed.
- AVALON in platinum-resistant ovarian cancer is now recruiting 40 patients in Stage 1, and management said more than a quarter of that first 40 have already been enrolled.
- The company ended 2022 with $21.2 million of cash after a $9 million raise in December, which management says funds operations into the second half of 2023.
- IMV engaged Stonegate to explore strategic options, with management suggesting a formal collaboration or combination may be the best path in a constrained funding environment.
IMV reported a 2022 net loss of $38 million versus a net loss of $36.6 million in 2021, an increase of $1.4 million. Management said the higher loss was largely due to increased loan interest after drawing down $10 million of venture debt in the second quarter. R&D expenses were described as comparable to the prior year despite startup costs for two global late-stage clinical trials. The company raised $9 million in December and ended December 31 with $21.2 million in cash, which management said should take it into the second half of 2023 and cover completion of Stage 1 VITALIZE data plus an early read of AVALON Stage 1 trends. No revenue or EPS figures were stated on the call.
Andrew Hall framed IMV as a platform company with a differentiated cancer vaccine approach and said the clinical data are validating the DPX technology. He emphasized that VITALIZE is showing confirmed complete responses in a very refractory DLBCL population and that AVALON is being advanced as a registration-oriented study. His tone was upbeat about the science but pragmatic about the capital markets, saying small-cap biotech financing is difficult and that IMV is exploring strategic alternatives to help get the drug to market.
No CFO formal remarks were provided in the transcript; the financial commentary came from the CEO. Hall said the company ended 2022 with a $38 million net loss, up from $36.6 million in 2021, mainly because of interest expense tied to the $10 million venture debt drawdown. He also said R&D was comparable year over year despite two late-stage global trial startups, and that the $9 million December financing lifted cash to $21.2 million, enough to fund the company into the second half of 2023.
Analysts pressed on timing and disclosure of Stage 1 data for VITALIZE and AVALON. Management said full disclosure is targeted for the third quarter, likely timed around summer conferences, with durability data potentially later in the year, possibly at ASH. They also addressed the two non-evaluable patients in the early VITALIZE readout, explaining that these were very sick patients who progressed or died during screening and would be over-enrolled around, not evidence of cherry-picking. Questions about strategic options and supply were answered by saying CDMO work has already been shifted to support commercial supply and that Stonegate is helping evaluate formal collaboration options.
The bull case from this call is that IMV is seeing confirmed complete responses in an extremely refractory cancer population, without systemic toxicity, across multiple scans. Management also said the same platform has shown signal in bladder and ovarian cancer, and that the company has enough cash to reach important near-term readouts while pursuing strategic interest from outside parties.
The main risks are that the data are still early, the company is dependent on future Stage 1 readouts to prove durability and broader response, and the market has reacted negatively despite positive signals. Management also highlighted that small-cap biotech financing is difficult, that additional over-enrollment may be needed because patients are too sick to remain evaluable, and that the company may need a formal collaboration or other strategic transaction to fully advance the program.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 11.71M
- Float Shares
- 11.71M
Our IMVIF coverage
Recent articles, reports, and earnings notes.
No research on IMVIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMVIF report →